Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance...
Transcript of Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance...
![Page 1: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/1.jpg)
Target therapy: first line?
Tommaso De Pas
European Institute of Oncology
![Page 2: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/2.jpg)
EGFRTKI monotherapy
![Page 4: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/4.jpg)
Giaccone, JCO 2004
INTACT-1
1093 pts, 66-72% IV stadio
9.9 vs 9.9 vs 10.9 ms
CDDP + GCB +
P: .4
![Page 5: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/5.jpg)
INTACT-1
INTACT-2
… IDEAL 1- IDEAL 2
![Page 6: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/6.jpg)
On average
Estimating the magnitude of the treatment effect
![Page 7: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/7.jpg)
![Page 8: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/8.jpg)
First line treatment in selected patients: evidence from randomized trial
Mok et al NEJM 2009
Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
patients in East Asia who had advanced pulmonary
adenocarcinoma and who were nonsmokers or former light
smokers
![Page 9: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/9.jpg)
IPASS: PFS
Fukuoka et al JCO 2011
Exon 19
deletion L858R
![Page 10: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/10.jpg)
Mok et al NEJM 2009
![Page 11: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/11.jpg)
First line treatment in selected patients: evidence from randomized trial
![Page 12: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/12.jpg)
Han et al, JCO 2012
First SIGNAL
159 pts: gefitinib
150 pts: GP
![Page 13: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/13.jpg)
EGFRTKI combined with
chemotherapy
![Page 14: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/14.jpg)
Mok T, ESMO 2012 FASTACT2
Randomized, placebo-controlled, phase 3 study
Patients with untreated stage IIIB/IV NSCLC and ECOG
PS 0/1 received up to 6 cycles of gemcitabine (1,250 mg/m2
on d1 & 8) plus platinum (carboplatin AUC = 5 or cisplatin
75 mg/m2 on d1) q4w, with either intercalated erlotinib (150
mg/day on d15-28; GC-E; n = 226) or placebo (GC-P; n =
225).
Pts without progression received maintenance erlotinib or
placebo until progression, unacceptable toxicity
or death.
![Page 15: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/15.jpg)
Mok T, ESMO 2012 FASTACT2
mPFS 6.0 vs 7.6 HR 0.5
mOS 15.2 vs 18.3 HR 0.7
Overall results, updated
ESMO 2012
… INTACT 1 – INTACT-2
IDEAL 1- IDEAL 2 …
![Page 16: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/16.jpg)
Mok T, ESMO 2012
FASTACT2
EGFR: 241 tested
97 EGFR M+ 49 erlotinib, 46 placebo
136 EGFR WT 69 erlotinib, 67 placebo
EGFR M+
PFS 6.9 vs 16.8 HR 0.2
OS 20.6 vs 31.4 HR 0,4 (p= .009)
EGFR WT
PFS 5.9 vs 6.7
OS 12.2 vs 14.9 (not sgn)
![Page 17: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/17.jpg)
Mok T, ESMO 2012 FASTACT2
Conclusion
EGFR M+ pts benefit with intercalated erlotinib
EGFRWT pts: not detrimental -> to be considered for EGFR
unknown pts
Results not due to unbalance in post randomization treatment:
85% of EGFR M+ in the placebo arm received erlotinib after
progression
![Page 18: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/18.jpg)
![Page 19: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/19.jpg)
![Page 20: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/20.jpg)
91% Overall population: 40% EGFR M+ and 60% EGFRWT
![Page 21: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/21.jpg)
Erlotinib
Erlotinib
+ CT
![Page 22: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/22.jpg)
Conclusion:
EGFR M+ -> EGFRTKI
EGFR M+ receiving CT -> + EGFRTKI
(FASTACT2)
EGFR ? -> adding EGFRTKI is not
detrimental in M- and it is better in M+
(FASTACT2)
![Page 23: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/23.jpg)
EGFRTKI: only EGFR
mutation?
![Page 24: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/24.jpg)
Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST
Trial
Douillard JCO 2010
Progression free survival
(A) high EGFR copy number
(B) low EGFR copy number
(C) EGFR protein expression positive
(D) EGFR protein expression negative
(E) mutant EGFR
(F) wild-type EGFR
(G) mutant KRAS
(H) wild-type KRAS.
![Page 25: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/25.jpg)
Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST
Trial
Douillard JCO 2010
![Page 26: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/26.jpg)
Biomarker Analyses and Final Overall Survival
Results
IPASS
Fukuoka et al JCO 2011
![Page 27: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/27.jpg)
Biomarker Analyses and Final Overall Survival
Results
IPASS
Fukuoka et al JCO 2011
In all, 1,217 patients were randomly assigned.
Biomarkers analyzed were:
EGFR mutation (437 patients evaluable)
EGFR gene copy number (406 patients evaluable)
EGFR protein expression (365 patients evaluable)
![Page 28: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/28.jpg)
Fukuoka et al JCO 2011
PFS EGFR M+
Copy n° H
EGFR M+
Copy n° L
EGFR M-
Copy n° H
EGFR M-
Copy n° L
![Page 29: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/29.jpg)
Fukuoka et al JCO 2011
PFS
EGFR mutations are the strongest predictive biomarker for
PFS and tumor response to first-line gefitinib versus
carboplatin/paclitaxel.
The predictive value of EGFR gene copy number was driven
by coexisting EGFR mutation (post hoc analysis).
![Page 30: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/30.jpg)
EGFRTKI: OS
![Page 31: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/31.jpg)
IPASS: Fukuoka et al JCO2011
Overall population
EGFR M unknown EGFR M-
EGFR M+
OS
![Page 32: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/32.jpg)
OS
Treatment-related differences observed for PFS in the EGFR
mutation–positive subgroup were not apparent for OS.
OS results were likely confounded by the high proportion of
patients crossing over to the alternative treatment.
IPASS: Fukuoka et al JCO2011
![Page 33: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/33.jpg)
Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of
patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a
randomised multicentre, open-label, phase 3 study
Ciuleanu et al Lancet Oncology 2012
Second-line in chemo-refractory patients
![Page 34: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/34.jpg)
TITAN
Ciuleanu et al Lancet Oncology 2012
Second-line in chemo-refractory patients
Up to four cycles of first-line platinum doublet chemotherapy
PD during / immediately after CT
erlotinib 150 mg/day vs chemotherapy (1:1)
docetaxel or pemetrexed regimens, at the treating
investigators' discretion
![Page 35: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/35.jpg)
TITAN
Ciuleanu et al Lancet Oncology 2012
![Page 36: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/36.jpg)
TITAN
Ciuleanu et al Lancet Oncology 2012
(A) in the intention-to-treat population
(B) excluding patients with squamous-
cell carcinoma
(C) in patients with EGFR wild-type
tumour
(D) in patients with EGFR -activating
mutation-positive tumour
![Page 37: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/37.jpg)
EGFRTKI: don’t forget tumor
response
![Page 38: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/38.jpg)
![Page 39: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/39.jpg)
WHIC MUTATION IS
BETTER?
![Page 40: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/40.jpg)
Fukuoka et al JCO 2011
IPASS: PFS
PFS was significantly longer for gefitinib versus
carboplatin/paclitaxel in both the exon 19 deletions (HR, 0.38;
95% CI, 0.26 to 0.56) and the exon 21 L858R mutation (HR,
0.55; 95% CI, 0.35 to 0.87) subgroups.
Within-treatment analysis indicated no significant difference
in PFS with gefitinib in the exon 19 deletions versus exon 21
L858R mutation subgroup (HR, 0.78; 95% CI, 0.51 to 1.19).
![Page 41: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/41.jpg)
IPASS: PFS
Fukuoka et al JCO 2011
Exon 19
deletion L858R
![Page 42: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/42.jpg)
Fukuoka et al JCO 2011
IPASS: ORR
Exon 19 deletions: significantly higher with gefitinib
84.8% vs 43.2%; OR, 7.23; 95% CI, 3.19 to 16.37
L858R: higher but not statistically significant
60.9% v 53.2%; OR, 1.41; 95% CI, 0.65 to 3.05
![Page 43: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/43.jpg)
EGFRTKI: only gefitinib /
erlotinib?
![Page 44: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/44.jpg)
Afatinib(ErbB-family blocker) : LUX – lung 3
345 chemo-naive pts
Afatinib 40 mg (230pts)
Cisplatin + Pemetrexed (115 pts )
Del 19: 49%; L858R: 40%
other mutations, 11%.
ASCO 2012 Dr Yang
R (2:1)
EGFR M+
![Page 45: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/45.jpg)
LUX-lung 3
mPFS: 11.1 vs 6.9 mos; HR 0.58 [0.43–0.78] p=0.0004
308 pts with Del19/L858R: median PFS was 13.6 vs 6.9
mos (HR=0.47 [0.34–0.65]; p<0.0001).
ORR: 56% vs 23%; p<0.0001
Delay in time to deterioration of cancer-related symptoms
of cough (HR=0.60, p=0.0072) and dyspnea (HR=0.68,
p=0.0145)
![Page 46: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/46.jpg)
DACOMITINIB
![Page 47: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/47.jpg)
DACOMITINIB
![Page 48: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/48.jpg)
DACOMITINIB
DACOMITINIB (PF-00299804), AN IRREVERSIBLE PAN-HER
TYROSINE KINASE INHIBITOR , FOR FIRST-LINE TREATMENT
OF EGFR-MUTANT OR HER2- MUTANT OR -AMPLIFIED LUNG
CANCERS
M. Kris et al, ESMO 2012
![Page 49: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/49.jpg)
DACOMITINIB (PF-00299804), AN IRREVERSIBLE PAN-HER
TYROSINE KINASE INHIBITOR , FOR FIRST-LINE TREATMENT
OF EGFR-MUTANT OR HER2- MUTANT OR -AMPLIFIED LUNG
CANCERS
EGFR mutated 45 pts
CR 0
PR 76%
SD 22%
PD 1%
mPFS 18 mos
PFS 12 m 76%
Ex 19 = L858R
![Page 50: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/50.jpg)
DACOMITINIB (PF-00299804), AN IRREVERSIBLE PAN-HER
TYROSINE KINASE INHIBITOR , FOR FIRST-LINE TREATMENT
OF EGFR-MUTANT OR HER2- MUTANT OR -AMPLIFIED LUNG
CANCERS
HER-2 mut /ampl 22 pts
CR 0
PR 14%
SD 27%
PD 45%
mPFS 1,9 mos
1 liver tox G5
![Page 51: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/51.jpg)
FIRST-IN-HUMAN DOSE-FINDING STUDY OF THE ALK/EGFR
INHIBITOR AP26113 IN PATIENTS WITH ADVANCED
MALIGNANCIES S. Gettinger et al, ESMO 2012
ALK+
Crizotinib
naive
ALK+
Crizotinib
pretreated
EGFR+
EGFRTKI
pretreated
RR 2/2 6/9 1 RP > 120 mg
Too early
Duration of
response
9 mos 6 mos
Dose > 90 mg
![Page 52: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/52.jpg)
EGFRTKI
only gefitinib / erlotinib?
![Page 53: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/53.jpg)
AFATINIB + CETUXIMAB
EGFR mutation positive adenocarcinoma
Progressing after erlotinib / gefitinb
T790M + (53) T790M- (42) TOT
RR 32% 28% 30%
CB 81% 64% 75%
PD 13% 21% 16%
Duration of response 6.4m 9m 8m
mPFS 4,7 m
![Page 54: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/54.jpg)
![Page 55: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/55.jpg)
ALK?
![Page 57: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/57.jpg)
ROS-1?
![Page 58: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/58.jpg)
![Page 59: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/59.jpg)
HER-2?
![Page 60: Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok](https://reader036.fdocuments.in/reader036/viewer/2022071101/5fda0eef30467c029d3a5ca5/html5/thumbnails/60.jpg)
N pts DCR
Trastuzumab based CT
15 96%
Afatinib 4 100%
Lapatinib 2 pts 0
Masatinib 1 0
Mazeires et al ESMO 2012